Skip to content
← Back to feed
Christopher H. Smith (R-NJ)
Christopher H. Smith
Republican·New Jersey

The abortion pill is extremely dangerous to womenSmith applauds federal appeals court’s ruling in Louisiana v. FDA to pause the Biden FDA’s mail-order abortion drug scheme

Rep. Chris Smith (R-NJ), Co-Chair of the Congressional Pro-Life Caucus and leader of a congressional amicus brief in support of Louisiana Attorney General Liz Murrill, issued the following statement in response to the Fifth Circuit Court of Appeals’ ruling in The State of Louisiana v. U.S. Food and Drug Administration (FDA), which halted the Biden Administration’s dangerous mail-order abortion pill policy while litigation continues: “Today’s ruling, which takes effect nationwide, underscores the extreme dangers posed to women by the Biden FDA’s 2023 decision to eliminate the longstanding in-person dispensing requirement for the chemical abortion drug mifepristone. “Mifepristone—the baby poison pill—barbarically starves unborn babies to death and is extremely harmful to women. A historic report released by the Ethics and Public Policy Center found that more than one out of ten (10.93%) women who take this dangerous pill experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days. “‘Abortion President’ Joe Biden’s FDA negligently and inexcusably allowed mifepristone to be easily ordered online and delivered through the mail, all without any in-person medical visits. The FDA’s reckless policy has endangered the lives of mothers and their unborn babies and prevented medical professionals from screening for contraindications, coercion, or other major health concerns. “Putting a pause on the egregious practice of mail-order abortion will help save countless lives, as the fight to remove mifepristone from the market continues.” ###

Source: https://chrissmith.house.gov/news/documentsingle.aspx?DocumentID=415580
Captured:
Record ID: c3ce143e-f23e-441d-8ef9-2e25fa982996

Issued within 24 hours

Other senators' releases published in the day before or after this one.